The company's US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market after having received approval to market it from the US Food and Drug Administration, according to a statement by Lupin.
Lupin's product is generic equivalent of Eisai Inc's Aciphex delayed-release tablets, 20mg, and is indicated for the treatment of gastroesophageal reflux disease, it added.
According to IMS MAT Jun 2013 sales data, Aciphex delayed-release tablets, 20mg, had annual US sales of around $864.3 million.
Shares of Lupin were trading at Rs 886.30 a piece on the BSE in late afternoon trade, up 0.30 per cent from its previous close.
The photograph is used for representational purpose only
India's 25 RICHEST people, Dilip Shanghvi top gainer
Now, US FDA gets a call from Indian pharma companies
Economy: No RECOVERY yet in sight
Lupin gets USFDA nod for additonal strengths of cholesterol drug
UK health regulator withdraws nod for another Wockhardt unit